SecBot SecBot

LSTA drug pipeline

LISATA THERAPEUTICS, INC. · 4 rated drugs
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
4
1 bearish · 3 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2b
Time to marketAt least 3-5 years — Phase 2b data expected Q4 2027, followed by potential Phase 3 trials and regulatory filing

MAR001/005 Updated Oct 24

What to watch

The November 9 stockholder vote is the immediate binary catalyst, failure to approve Series C conversion and reverse split could trigger cash settlement obligations and Nasdaq delisting risk. For MAR001/005 specifically, Phase 2b topline data is not expected until Q4 2027, over a year away. The extreme dilution (~2.39% legacy ownership) means LSTA stock is now effectively a proxy for Marea Therapeutics' pipeline, but with corporate governance overhangs that need resolving first.

Bull case
  • $225 million PIPE from top-tier investors (RA Capital, Forbion, Third Rock, Alpha Wave) provides substantial cash runway through multiple clinical milestones
  • Severe hypertriglyceridemia is a serious condition with limited treatment options; a successful Phase 2b could position MAR001/005 for significant market opportunity
  • Analyst consensus shows 6 Buy/Strong Buy ratings vs 3 Hold (period Oct 2026), indicating institutional optimism about the combined pipeline
Bear case
  • Legacy LSTA shareholders diluted to ~2.39% ownership, the stock is now a Marea Therapeutics proxy with minimal continuity from prior Lisata value
  • Phase 2b topline data not expected until Q4 2027 (>12 months away), leaving a long data desert with no near-term drug catalyst
  • Stock trades near $1.00, well below Nasdaq $4.00 minimum bid price; failure of November 9 reverse-split vote could trigger delisting
● neutral
Impact
PhasePhase 2b
Time to marketSeveral years away at minimum. Phase 2b data have not yet been reported; even on an accelerated timeline, Phase 3 trials and FDA review would take multiple additional years post-readout. The company is also in corporate restructuring mode post-reverse-merger, which may further delay pipeline execution.

MAR002 Updated Oct 24

What to watch

MAR002 has no hard dated catalyst in the next 12 months. The stock's primary near-term binary is the November 9, 2026 shareholder vote on the Series C conversion and reverse stock split, essential for the merged entity's Nasdaq listing. Monitor that vote for trading around the LSTA ticker; the drug-specific readout for MAR002 is likely 12+ months out and should not be the basis for a near-term position.

Bull case
  • Marea's reverse merger brought a ~$225 million PIPE, giving the combined entity a strong balance sheet to fund MAR002's Phase 2b development without near-term dilution risk.
  • Acromegaly is a well-understood orphan indication with established regulatory pathways and multiple approved comparators, reducing development risk vs. novel targets.
  • The oral acromegaly market is being validated by PALSONIFY (paltusotine), which Vertex is acquiring Crinetics for ~$10 billion, confirming significant commercial interest in the space.
Bear case
  • Legacy Lisata shareholders retain only ~2.39% of the combined entity; the stock's correlation to MAR002's success is extremely diluted for pre-merger holders.
  • The company faces an existential Nasdaq listing risk, stock trades around $1.00 vs. the $4.00 minimum bid requirement, requiring a reverse split and shareholder approval.
  • HC Wainwright downgraded LSTA to Neutral from Buy in May 2026, reflecting significant uncertainty around the company's strategic direction.
▼ bearish
Impact
PhasePhase 2
Time to marketCertepetide is in Phase 2 clinical development with no registered Phase 3 trial underway. Given the company's strategic pivot to cardioendocrine diseases, the timeline to potential approval is highly uncertain and likely several years away, if pursued at all.

certepetide Updated Nov 19

What to watch

Certepetide is now a legacy pipeline asset for Lisata, which has pivoted to cardioendocrine diseases via the Marea acquisition. No upcoming binary catalyst (PDUFA, pivotal readout) is scheduled for certepetide. The final ASCEND Phase 2b data, expected Q1 2026, may have been released without fanfare given the corporate transformation. Watch for any out-licensing or partnership deal for certepetide, or its deprioritization in future pipeline updates.

Bull case
  • Certepetide showed encouraging Phase 2b ASCEND trial data: Cohort A median overall survival of 12.68 months vs 9.72 months for placebo, with 4 complete responses vs 0, and Cohort B corroborated with positive signals in progression-free survival and objective response rate.
  • The drug has a novel mechanism as an iRGD cyclic peptide that activates a tumor-specific active transport pathway, potentially enhancing delivery of a wide range of anti-cancer drugs including immunotherapies and ADCs.
  • Lisata continues to build IP protection: a composition of matter patent (protection to 2040) was granted in July 2025, and a new method of use patent was granted in October 2026, suggesting ongoing commitment to the asset.
Bear case
  • Certepetide is no longer Lisata's lead asset; after the September 2026 Marea acquisition, the company's focus shifted to cardioendocrine diseases (MAR001, MAR002), and pre-transaction Lisata shareholders retained only ~2.39% of the combined entity, making certepetide a minor legacy program.
  • The planned Phase 3 development for certepetide, which management discussed in early 2025, appears to have been deprioritized or shelved following the failed Kuva merger and the Marea reverse merger.
  • Both HC Wainwright (to Neutral) and Brookline Capital (to Hold) downgraded the stock in 2026, and analyst coverage is now stale (last action May 2026). The stock trades at $0.91, near its 52-week low of $0.86.
● neutral
Impact
PhasePreclinical
Time to marketUnknown; MAR003 is preclinical and no clinical trial enrollment has been publicly identified. If it follows the siRNA development path, it would likely be several years from potential commercialization.

MAR003 Updated Nov 14

What to watch

MAR003 is too early-stage (preclinical) to drive LSTA's near-term share price. Investors should instead focus on the November 30, 2026 annual meeting vote for Series C conversion (which unlocks the ~350M share resale registration overhang) and on upcoming clinical catalysts for MAR001 (Phase 2b hypertriglyceridemia data presented at AHA Nov 6-9, 2026) and MAR002 (Phase 2 acromegaly trial enrollment).

Bull case
  • MAR003 is part of a $292.9M IPR&D allocation from the Marea acquisition, signaling the acquiring company (backed by a $225M PIPE from top healthcare investors) sees meaningful value in the preclinical pipeline.
  • Marea's siRNA platform (which MAR003 is likely part of) leverages human genetics for first-in-class cardioendocrine targets, a validated approach that has produced MAR001 (positive Phase 2b data) and MAR002 (promising Phase 1 data).
  • The combined company has a strong syndicate of healthcare-focused investors (RA Capital, Perceptive, Third Rock, venBio, Sofinnova, Forbion) that participated in the $225M PIPE, providing cash runway.
Bear case
  • MAR003 is a preclinical/early-stage asset with no disclosed mechanism, no clinical data, and no identified catalyst timeline; it is likely years from entering clinical trials.
  • LSTA faces massive dilution risk: the S-3 shelf registers ~350M shares for resale, roughly 32x the current 10.8M float, creating severe overhang.
  • The company is a combined entity with no approved products, a ~$12M market cap, and pro forma net losses of ~$49.8M in just H1 2026 alone.

Other drugs in filings and trials

no drug report yet

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
certepetideA Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsPhase 2Completed · results66Apr 5, 2026
CLBS16A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular DysfunctionPhase 2Terminated · results34Sep 28, 2022